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Highlights 
 Bacteriophages represent a therapeutic alternative against MDR 
Enterobacteriaceae. 
 Three commercial phage cocktails were tested against 101 E. coli and Proteus 
spp. isolates. 
 E. coli susceptibility to PYO, INTESTI and Septaphage was 61%, 67% and 9%, 
respectively. 
 Proteus spp. susceptibility to PYO, INTESTI and Septaphage was 29%, 39% and 
19%, respectively. 
 New phages need to be integrated in such preparations to target more MDR 
pathogens. 
ABSTRACT 
Objectives: Bacteriophages may represent a therapeutic alternative to treat infections 
caused by multidrug-resistant (MDR) pathogens. However, studies analysing their activity 
against MDR Enterobacteriaceae are limited. 
Methods: The in vitro lytic activity of three commercial bacteriophage cocktails (PYO, 
INTESTI and Septaphage) was evaluated against 70 Escherichia coli and 31 Proteus 
spp. of human and non-human origin. Isolates were characterised by phenotypic and 
genotypic methods and included 82 MDR strains [44 extended-spectrum--lactamase 
(ESBL)-producers (18 CTX-M-15-like, including ST131/ST648 E. coli); 27 plasmid-
mediated AmpC -lactamase (pAmpC)-producers (23 CMY-2-like, including ST131 E. 
coli); 3 ESBL + pAmpC-producers; and 8 carbapenemase-producers]. Phage 
susceptibility was determined by the spot test. 
3 
 
Results: Escherichia coli susceptibility to PYO, INTESTI and Septaphage was 61%, 67% 
and 9%, whereas that of Proteus spp. was 29%, 39% and 19%, respectively. For the 
subgroup of ESBL-producing E. coli/Proteus spp., the following susceptibility rates were 
recorded: PYO, 57%; INTESTI, 59%; and Septaphage, 11%. With regard to pAmpC-
producers, 59%, 70% and 11% were susceptible to PYO, INTESTI and Septaphage, 
respectively. Five of eight carbapenemase-producers and three of four colistin-resistant 
E. coli were susceptible to PYO and INTESTI. 
Conclusions: This is the first study analysing the activity of the above three cocktails 
against well-characterised MDR E. coli and Proteus spp. The overall narrow spectrum of 
activity observed could be related to the absence of specific bacteriophages targeting 
these contemporary MDR strains that are spreading in different settings. Therefore, 
bacteriophages targeting emerging MDR pathogens need to be isolated and integrated 
in such biopreparations. 
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1. Introduction 
Treatment of infections caused by multidrug-resistant (MDR) Enterobacteriaceae 
represents a continuous challenge. These pathogens are frequently resistant to 
extended-spectrum cephalosporins owing to the production of extended-spectrum -
lactamases (ESBLs) and/or plasmid-mediated AmpC -lactamases (pAmpCs) [1–3]. 
Moreover, even the last therapeutic options, namely carbapenems and polymyxins, are 
under attack due to the spread of carbapenemase- and/or MCR-1/2-producing strains, 
respectively [4,5]. 
 
In this overall scenario, the use of bacteriophages (highly species-specific self-
propagating viruses that can infect and lyse bacteria) could represent a valid therapeutic 
alternative to treat infections caused by extended-spectrum cephalosporin- and/or 
carbapenem-resistant Gram-negative pathogens [6,7]. Bacteriophage therapy is part of 
the standard medical practice in the former Soviet Union countries. In contrast, in Western 
nations the use of phage therapy is unfamiliar and this has generated a lack of clinical 
studies analysing the efficacy of this possible alternative therapeutic approach [6,7]. 
Therefore, most of the available scientific literature in English presents data obtained only 
with animal models. For instance, bacteriophage treatment was effective in in vivo models 
with ESBL-producing Escherichia coli, including those belonging to the hyperepidemic 
clone of sequence type 131 (ST131) [8–10]. 
 
Whilst data regarding the in vitro activity of bacteriophages against E. coli and 
Staphylococcus aureus are available, studies analysing their activity against large 
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collections of MDR Enterobacteriaceae are very limited. Fitzgerald-Hughes et al. showed 
that 89% of human ESBL-producing E. coli isolates were susceptible to at least one of 
four bacteriophage cocktails [11]. However, strains were defined as ESBL-producers only 
using the phenotypic European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) criteria; moreover, pAmpC- or carbapenemases-producers were not tested 
and multilocus sequence typing (MLST) was not performed to define the ST [11]. In 
another study, Sybesma et al. assessed the susceptibility of ESBL-producing E. coli and 
Klebsiella pneumoniae strains, all isolated from patients suffering from urinary tract 
infection (UTI), to four Georgian bacteriophage cocktails and several mono-phage 
preparations [12]. Their results showed great variability, with lytic activity ranging from 
66% to 93% for E. coli and from 0% to 100% for K. pneumoniae [12]. Consistent results 
were also obtained by Gundogdu et al. who recently tested ESBL-producing E. coli from 
patients’ blood and urine samples [13]. However, for these two latter studies, ESBL 
production was only phenotypically defined and no information on the ST or resistance 
gene profiles of the bacteria was presented [12,13]. 
 
To our knowledge, the activity of commercially available bacteriophage cocktails against 
well-defined MDR E. coli strains of animal and food origin has never been described. In 
the same context, data regarding Proteus spp. isolates detected in different settings are 
completely lacking. Therefore, in this work we aimed to assess the lytic effect of three 
commercial bacteriophage preparations, all available to the public in Georgia, on a large 
collection of well-characterised human and non-human E. coli and Proteus spp. strains. 
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2. Materials and methods 
2.1. Bacteriophage cocktails 
Three commercially available bacteriophage cocktails produced by Georgian institutions 
located in Tbilisi were tested. According to the manufacturers, they are all sterile-filtrate 
phage lysates of different bacterial species as listed below. The preparation lot numbers 
implemented during the present work are indicated in parentheses, along with the 
declared phage concentration specified by the provider. 
 
2.1.1. PYO Bacteriophage 
PYO Bacteriophage (lot # M1-801; Eliava BioPreparations, Tbilisi, Georgia) targets E. 
coli, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Staphylococcus spp. 
and Streptococcus spp. The specified concentration was 1  105–6 plaque-forming units 
(PFU)/mL. 
 
2.1.2. INTESTI Bacteriophage 
INTESTI Bacteriophage (lot # M2-801; Eliava BioPreparations) targets E. coli, P. 
mirabilis, P. vulgaris, Salmonella Paratyphi A and B, Salmonella Typhimurium, 
Salmonella Enteritidis, Salmonella Choleraesuis, Salmonella Oranienburg, Shigella 
flexneri, Shigella sonnei, Shigella newcastle, P. aeruginosa, Staphylococcus spp. and 
Enterococcus spp. The specified concentration was 1  105–6 PFU/mL. 
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2.1.3. Septaphage 
Septaphage (lot # 01.05.15; Biochimpharm, Tbilisi, Georgia) targets different serogroups 
of enteropathogenic E. coli, Proteus spp., S. Paratyphi A and B, S. Typhimurium, S. 
Choleraesuis, S. Oranienburg, S. Enteritidis, S. flexneri (serogroups 1, 2, 3, 4 and 6), S. 
sonnei, P. aeruginosa, Staphylococcus spp. and Enterococcus spp. The specified 
concentration was 1  105 PFU/mL. 
 
All three phage cocktails are available to the public without prescription in Georgia. In 
particular, PYO is used to treat purulent skin, surgical, oral, enteral and gynaecological 
infections, whereas INTESTI and Septaphage are implemented for intestinal infections. 
 
2.2. Bacterial collection and characterisation 
The in vitro activity of the above three phage preparations was evaluated against a 
collection of 70 well-characterised and contemporary E. coli isolates of human (n = 31), 
animal (n = 22) and food (n = 12) origin as well as 5 laboratory controls (Table 1). Overall, 
the majority of strains (43/70; 61%) were detected in the last 5 years (2015, n = 23; 2014, 
n = 2; 2013, n = 3; and 2012, n = 15). Most strains were previously characterised by 
phenotypic [minimum inhibitory concentration (MIC) determination using microdilution 
Trek panels] and genotypic [CheckPoints CT103 or CT103XL microarray, 
PCR/sequencing for bla genes, plasmid content by PCR-based replicon typing (PBRT) 
and MLST] methods [1,3,5,14–18]. In particular, the collection included 37 ESBL-
producers (18 CTX-M-15-like), 21 pAmpC-producers (17 CMY-2-like), 2 ESBL + pAmpC-
producers, and 7 carbapenemase-producers (4 NDM, 2 OXA-48 and 1 IMP). Four 
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colistin-resistant strains were also included, one of which carried the mcr-1 resistance 
gene [5]. 
 
In addition, 21 well-characterised P. mirabilis of human (n = 18) and food (n = 3) origin [3] 
were tested, along with 10 P. vulgaris responsible for human bacteraemia at Bern 
University Hospital, University of Bern (Bern, Switzerland). Overall, 7 ESBL-producers (4 
VEB, 2 TEM and one CTX-M), 6 pAmpC-producers (all CMY-2), 1 with CTX-M-9-/CMY-
2-like and 1 carbapenemase (NDM)-producer were tested. Most strains (27/31, 87%) 
were detected in the last 5 years (2016, n = 9; 2015, n = 5; 2014, n = 6; 2013, n = 3; and 
2012, n = 4) (Table 2). 
 
Species identification of all E. coli and Proteus spp. strains was done using matrix-
assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF/MS) 
(Bruker Daltonics, Leipzig, Germany). Strains were defined as MDR according to 
Magiorakos et al. [19]. 
 
2.3. Susceptibility to bacteriophage cocktails 
Phage susceptibility was determined by implementing the spot test with Double Agar 
Overlay Plaque Assay [20]. Briefly, a 10 L loop of fresh overnight culture was grown for 
2 h in 5 mL of brain–heart infusion (BHI) broth (Becton Dickinson, Allschwil, Switzerland) 
at 37 C in a shaking incubator to reach mid-log bacterial phase. For each host bacteria, 
100 L of a 0.5 McFarland bacterial suspension was mixed in a BHI agarose matrix (‘top 
agar’, 0.6%), which was then distributed to solidify on a standard BHI agar plate (‘bottom 
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agar’, 1.5%, dried for 2 h before use at room temperature). After drying, 10 L of each of 
the four phage suspensions was spotted on the plate and was incubated overnight. 
 
The next day, lysis zones (if any) were quantified using a common system assessing the 
success of phage infection [20]. In particular, strains showing confluent lysis (i.e. complete 
clearing: ‘++++’), semiconfluent lysis (i.e. clearing throughout but with faintly hazy 
background: ‘+++’), opaque lysis (i.e. turbidity throughout the cleared zone: ‘++’) or 
‘tâches vièrges’ (i.e. individual clear or opaque plaques: ‘+’) were defined as susceptible 
to the phage compounds tested. Strains showing no activity (i.e. no clearing: ‘R’) were 
defined as resistant. 
 
All of the susceptibility tests were performed at the Institute for Infectious Diseases of the 
University of Bern between 29 August 2016 and 6 October 2016 by two of the authors 
(OJB and RT). The spot test was performed two times on different days, using vials 
belonging to different boxes (except for PYO, for which two vials of the same box were 
tested) and BHI broth/agar plates prepared in different sessions. Results were interpreted 
by at least three operators and showed consistency for all tested strains, with no 
difference greater than one ‘+’ between the two experiments (with very few exceptions, 
for which a third assay was performed). 
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3. Results and discussion 
3.1. Escherichia coli strains 
As shown in Table 3, the overall susceptibility of E. coli strains to PYO, INTESTI and 
Septaphage was 61.4% (including 7/70 with ‘+++’ and 6/70 with ‘++++’), 67.1% (including 
9/70 with ‘+++’ and 5/70 with ‘++++’) and 8.6% (including 4/70 with ‘++++’), respectively. 
In particular, PYO cocktail showed lytic activity against 67.7% (21/31), 50.0% (11/12) and 
66.7% (8/12) of human, animal and food strains, whereas the activities for INTESTI were 
64.5% (20/31), 63.6% (14/22) and 75.0% (9/12), respectively (Table 1). 
 
For the overall subgroup of the ESBL-producing E. coli strains (n = 37), the following 
susceptible rates were recorded: PYO, 54.0%; INTESTI, 56.7%; and Septaphage, 2.7% 
(Table 3). In the study by Fitzgerald-Hughes et al., 100 phenotypically defined ESBL-
producing E. coli were susceptible to PYO and INTESTI in 36% and 54% of cases, 
respectively [11]. Septaphage was not tested, but the authors indicated that two additional 
phage cocktails, not tested in the present study, were much more active (i.e. SES and 
ENKO, at 87% and 89%, respectively) [11]. In another analysis testing only nine ESBL-
producing E. coli strains, Sybesma et al. obtained the following susceptibility rates: PYO, 
78%; and INTESTI, SES and ENKO, all 89% [12]. 
 
With regard to the pAmpC-producing E. coli strains (n = 21), 71.4% and 85.7% were 
susceptible to PYO and INTESTI, respectively, whereas only 14.3% were susceptible to 
Septaphage. Moreover, five of seven carbapenemase-producers and three of four 
colistin-resistant strains (including the MCR-1-producer) were susceptible to PYO and 
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INTESTI, respectively (Tables 1 and 3). We highlight that no previous studies have 
analysed the lytic activity of commercial bacteriophage cocktails against this specific 
group of MDR E. coli strains. Data regarding the life-threatening carbapenem- and 
colistin-resistant strains were promising [4,5,21] but should be confirmed testing a larger 
collection of strains. 
 
In this study, five of seven E. coli strains belonging to the hyperepidemic clones ST131 
and ST648 [22] were susceptible both to PYO and INTESTI (Tables 1 and 3). We also 
emphasise that the activity of the phage compounds was relatively different even though 
the E. coli strains belonged to the same STs (e.g. see the results of the five ST131 and 
four ST420 strains in Table 1). These differences probably depend on the fact that some 
bacterial clones may acquire and develop different escape strategies (e.g. inhibition of 
CRISPR-Cas or phage adsorption systems) against bacteriophages [23]. Therefore, as 
recently explored for S. Typhimurium [24], further studies with a larger collection of 
hyperepidemic E. coli clones coupled with whole-genome sequence analyses should be 
performed to clarify the underlying molecular mechanisms that make each unique 
bacteria resistant to phage attack. 
 
3.2. Proteus spp. strains 
As anticipated, published data regarding the activity of commercial bacteriophage 
cocktails against Proteus spp. strains are lacking. In the present study, the overall 
susceptibility of Proteus spp. to PYO, INTESTI and Septaphage was 29.0% (including 
3/31 with ‘+++’ or ‘++++’), 38.7% (including 4/31 with ‘+++’ or ‘++++’) and 19.3% (including 
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5/31 with ‘+++’ or ‘++++’), respectively (Table 2 and 3). In particular, the following 
susceptibility rates were recorded for P. mirabilis and P. vulgaris, respectively: PYO, 
33.3% and 20.0%; INTESTI, 47.6% and 20.0%, and Septaphage, 28.6% and 0%. With 
regard to the MDR P. mirabilis strains (n = 15), 40.0% were susceptible both to PYO and 
INTESTI, whereas only 26.7% were susceptible to Septaphage (Table 3). Owing to the 
relatively small number of tested strains, larger collections of MDR Proteus spp. should 
be tested to confirm these results. 
 
3.3. Overall strains 
Surprisingly, Septaphage displayed an almost complete lack of activity both against E. 
coli and Proteus spp. strains. Moreover, a noteworthy variability between the two 
preparations expected to target the same bacterial species (i.e. INTESTI and 
Septaphage) could be noted (Table 3). This may be linked to the different content in terms 
of strains-specific bacteriophages with lytic activity. However, to our knowledge, only the 
INTESTI preparation has been well characterised using metagenomic analyses [25]. 
Alternatively, the reason for such remarkable divergences among the phage compounds 
could rely on different production methods [26], leading to insufficient viral titre of the final 
biopreparation. In this context, we note that a concentration of 105–6 PFU/mL is indicated 
both for INTESTI and PYO, whereas the concentration is 105 PFU/mL for Septaphage. 
 
The overall narrow spectrum of activity of the cocktails observed against the MDR E. coli 
and Proteus spp. analysed in this study could be related to the absence of specific 
bacteriophages targeting these contemporary strains that are usually responsible for 
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human infections both in hospital and community settings [17,22,27–29]. Besides, it is 
remarkable that most of the fully antibiotic-sensitive P. mirabilis and P. vulgaris strains 
(10/16; 62.5%) were shown to be completely resistant to the bacteriophage cocktails with 
declared activity against such species. 
 
Therefore, the spectrum of activity of the above cocktails should be expanded integrating 
new lytic phages. We note for instance that Dufour et al. have recently selected a 
bacteriophage (LM33_P1) with lytic activity against ca. 65% of ST131 E. coli isolates 
tested and also able to significantly reduce the organ bacterial load in pneumonia, 
septicaemia and UTI in in vivo models [9]. Pouillot et al. isolated another bacteriophage 
(EC200PP) specific for E. coli ST131: although no data regarding its spectrum of activity 
against a collection of ST131 strains was provided, this phage demonstrated potent 
activity in sepsis and meningitis in vivo models [10]. 
 
A limited number of bacteriophages infecting Proteus spp. have so far been selected and 
studied [30,31]. Nevertheless, we underline that Melo et al. have recently isolated and 
characterised a novel bacteriophage (Pm5461) that was able to target all 26 Proteus spp. 
tested in the study. Unfortunately, the antimicrobial susceptibility phenotype of the strains 
and their year of collection were not defined [32]. 
 
Finally, we should note that the spot test can lead to an overestimation of positive results 
as a consequence of the ‘lysis-from-without’ phenomenon [33]. We are therefore aware 
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that the results of the current study might partially overestimate the susceptibility results 
for PYO and INTESTI compounds. 
 
4. Conclusions 
Escherichia coli and Proteus spp. are frequently responsible for UTIs and bacteraemia 
[27,34]. Furthermore, difficult-to-treat infections due to MDR E. coli and Proteus spp. are 
increasing worldwide, leading to higher morbidity and mortality rates [1,28,29,35]. We 
also note that such MDR pathogens can cause intestinal colonisation of humans [5,16] 
and animals [2,14,18,21], along with contamination of the food chain [3,36,37]. Since 
exchange of MDR strains among these settings has been demonstrated [2,18], this 
overall phenomenon, also known as the ‘One-Health concept’, contributes enormously to 
the expansion and spread of MDR Enterobacteriaceae [38]. 
 
In this scenario, we therefore explored the use of bacteriophages as a possible alternative 
to antibiotics. In particular, we assessed for the first time the in vitro susceptibility of a 
large collection of well-characterised E. coli and Proteus spp. to three commercial 
bacteriophage cocktails. This information is essential to understand whether these phage 
compounds can be hypothetically implemented in large scale to treat infections (e.g. 
UTIs) [6,7], to decolonise intestinal carriers and/or to decontaminate food stuffs [39] from 
current MDR E. coli and Proteus spp. 
 
As a result of the analysis, we observed neither strong lysis (‘+++’ to ‘++++’) for the 
majority of the tested strains, nor a wide spectrum of activity against the total number of 
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bacteria, especially regarding Proteus spp. The most active compound (INTESTI) showed 
ca. 70% and 40% activity against E. coli and Proteus spp., respectively (although only 
15–20% with activity ≥ ‘+++’). 
 
The great diversity of currently circulating MDR E. coli and Proteus spp. is partially 
exemplified by the bacterial collection studied here. The tested cocktails contained only 
a few bacterial viruses targeting such contemporary pathogens. Therefore, new 
bacteriophages active against emerging MDR strains need to be isolated and integrated 
in such biopreparations. Only in this way will phage libraries start to reflect the worldwide 
and actual situation of MDR and pandemic isolates [22]. Moreover, the newly isolated 
bacteriophages should also be well characterised [9,10,25,32] and should be produced 
according to Good Manufacturing Practice (GMP) standards in order to become, at a later 
stage, approved for clinical therapy [7,26]. 
 
To become a real alternative to standard antimicrobials, phage cocktails first need to be 
brought up to date in terms of clinically relevant strain-specific viral content [40]. Only then 
will the progress towards therapeutic use of bacteriophages for the management of 
difficult-to-treat infections caused by MDR organisms meet a ground to grow and flourish 
also in the Western world. 
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Table 1 
Characteristics of 70 multidrug-resistant Escherichia coli strains and their susceptibility 
to four commercial bacteriophage cocktails 
Strain ID Origin 
(source; 
year of 
isolation
) 
Main 
bla 
genes 
ST a Susceptibility 
according to EUCAST 
b 
Bacteriophage 
susceptibility c 
CT
X 
IP
M 
CI
P 
GE
N 
C
OL
PY
O 
INTE
STI 
Septap
hage 
4811.56 Human 
(vagina
l; 2011) 
CTX-
M-15 
ST1
31 
R S S S S R R R 
4901.28 Human 
(urine; 
2011) 
CTX-
M-15 
ST1
31 
R S R R S ++
+ 
+++ R 
LA120950
38/Ec-38 
Human 
(urine; 
2012) 
CTX-
M-15 
ST1
31 
R S R R S ++
+
+ 
+++ R 
4809.08 Human 
(liver 
absces
s; 
2011) 
CTX-
M-15 
ST6
48 
R S R R S R R R 
8-R MAC 
III 
Human 
(stool; 
2015) 
CTX-
M-15 
ST6
48 
R S R R S ++ ++ R 
MSA971 Poultry 
(cloacal
; 2010–
2011) 
CTX-
M-15 
ST5
33 
R S I R S R + R 
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83-R MAC 
III 
Human 
(stool; 
2015) 
CTX-
M-15 
ST3
94 
R S S S S R R R 
97R DrigI Human 
(stool; 
2015) 
CTX-
M-15 
ST2
91 
R S S S S + R R 
23-R DrigII Human 
(stool; 
2015) 
CTX-
M-15 
ST2
00 
S S S S S + + R 
8-R MAC I Human 
(stool; 
2015) 
CTX-
M-15 
ST2
45 
R S R R S + + R 
73-R 
chromB 
Human 
(stool; 
2015) 
CTX-
M-15 
ST4
12 
R S S S S ++ + R 
IMD0077/1
1 
Cattle 
(stool; 
2010–
2011) 
CTX-
M-15 
ST5
37 
R S R S S R R R 
Sidava Cat 
(stool; 
2015) 
CTX-
M-15 
ST7
3 
R S S S S R + R 
68-M3 
SupI 
Human 
(stool; 
2015) 
CTX-
M-
15-
like 
ST4
8 
R S S S S R R R 
97-R DrigII Human 
(stool; 
2015) 
CTX-
M-
15-
like 
ST8
41 
R S S S S R + R 
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29-R 
MacIII 
Human 
(stool; 
2015) 
CTX-
M-
15-
like 
ST3
49 
R S S S S + R R 
43-R Drig Human 
(stool; 
2015) 
CTX-
M-
15-
like 
ST6
17 
R S R S S R R R 
56-M3-Ec-
Col-R 
Human 
(stool; 
2015) 
CTX-
M-
15-
like 
ST6
30 
R S R S R ++
+
+ 
++++ R 
Ylraz I Dog 
(stool; 
2013) 
CTX-
M-1 
ST9
49 
R S S S S R R R 
IMD0041/1
1 
Swine 
(stool; 
2010–
2011) 
CTX-
M-1 
ST5
29 
R S I S S ++ + R 
5A Chicken 
meat 
(2012) 
CTX-
M-1 
ST2
48 
R S S S S R R R 
7A Chicken 
meat 
(2012) 
CTX-
M-1 
ST1
14 
R S S S S + + R 
7B Chicken 
meat 
(2012) 
CTX-
M-1 
na R S S S S ++
+ 
++++ 0 
11A Chicken 
meat 
(2012) 
CTX-
M-1 
ST1
30 
R S S S S + + R 
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9A Chicken 
meat 
(2012) 
CTX-
M-1 
ST6
02 
R S S S S + + R 
18A Chicken 
meat 
(2012) 
CTX-
M-1 
ST2
3 
R S S S S + +++ R 
20C Chicken 
meat 
(2012) 
CTX-
M-1 
na R S S S S ++ + R 
100-R-
ChromII 
Human 
(stool; 
2015) 
CTX-
M 
grou
p 1 
na R S S S S R R R 
100-R-Drig Human 
(stool; 
2015) 
CTX-
M 
grou
p 1 
ST1
55 
R S S S S + + ++++ 
Socra Dog 
(stool; 
2015) 
CTX-
M-14 
ST1
62 
R S S R S R R R 
11/IMD047
7 
Poultry 
(cloacal
; 2010–
2011) 
TEM-
52 
ST5
24 
I S I S S + + R 
IMD 
0050/11 
Poultry 
(cloacal
; 2010-
11) 
TEM-
52 
ST8
6 
R S S S S R R R 
4A Chicken 
meat 
(2012) 
TEM-
52 
ST2
3 
R S S S S + + R 
27 
 
100-R-Ec Human 
(stool; 
2015) 
TEM-
1 
(mcr-
1-
positi
ve) 
ST1
0 
S S R S R + + R 
MSA899 Poultry 
(cloacal
; 2010–
2011) 
SHV-
12 
ST2
1 
I S I S S R R R 
3A Chicken 
meat 
(2012) 
SHV-
12 
ST1
55 
R S S S S R R R 
15A Chicken 
meat 
(2012) 
SHV-
12 
ST1
55 
R S S S S R R R 
2390300 Human 
(wound
; 2015) 
CMY-
2 
ST1
31 
I S S S S + + R 
2402500 Human 
(respira
tory; 
2015) 
CMY-
33 
ST1
31 
R S S S S ++ +++ R 
MSA1088 Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST3
8 
R S I S S + + R 
MSA970 Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST4
20 
R S I S S ++
+ 
+++ R 
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MSA972 Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST4
20 
R S I S S ++
+
+ 
+++ + 
MSA992 Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST4
20 
R S I S S ++
+ 
++++ R 
11/IMD008
7 
Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST4
20 
R S I S S ++
+
+ 
++++ R 
MSA991 Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST5
39 
R S I S S + + R 
MSA935 Swine 
(nose; 
2010–
2011) 
CMY-
2 
ST5
39 
R S S S S + + R 
11/IMD012
9 
Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST9 R S I S S + + R 
11/IMD014
7 
Poultry 
(cloacal
; 2010–
2011) 
CMY-
2 
ST5
27 
R S I S S + + R 
Sinaj Cat 
(stool; 
2015) 
CMY-
2 
ST5
6 
R S S S S R + R 
29 
 
MSA967 Swine 
(nose; 
2010–
2011) 
CMY-
2 
ST2 R S R S S R R R 
MSA969 Swine 
(nose; 
2010–
2011) 
CMY-
2 
ST5
32 
R S I S S R R R 
MSA909 Poultry 
(cloacal
; 2010–
2011) 
CMY-
2-
like 
na R S S S S R R R 
1C Turkey 
meat 
(2012) 
CMY-
2 
ST1
17 
R S S S S + ++ R 
13C Chicken 
meat 
(2012) 
CMY-
2 
ST3
8 
R S S S S R + R 
2081272 Human 
(blood; 
2012) 
DHA na S S R S S + ++ + 
73-R Mac Human 
(stool; 
2015) 
DHA ST1
0 
S S S S S ++
+
+ 
+++ R 
GC 2919 Laborat
ory 
strain 
ACT-
1 
na R S S S S ++
+
+ 
+++ ++++ 
AH3966 Laborat
ory 
strain 
FOX na S S S S S R + R 
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2152061 Human 
(urine; 
2013) 
CTX-
M-
15-
/CM
Y-2-
like 
na R S R S S R R R 
804133/14 Human 
(stool; 
2014) 
CTX-
M-
15, 
CMY
-2 
ST1
17 
R S S R S + + R 
01C60-LF Human 
(stool; 
2013) 
OXA-
48, 
CTX-
M-9 
na R S R R S ++
+ 
++ R 
2265478 Human 
(urine; 
2014) 
OXA-
48 
na S S S R S ++ + R 
2058665 Human 
(na; 
2012) 
NDM-
1-
/CM
Y-2-
like 
na R R R R S + ++ R 
AC-IT-1 Human 
(urine; 
2010) 
NDM-
1, 
CTX-
M-15 
ST1
01 
R R R R S ++
+ 
++++ ++++ 
31 
 
2411192 Human 
(stool; 
2015) 
NDM-
1-
/CM
Y-2-
like 
na R R R S S R R R 
ATCC 
BAA-
2452 
Laborat
ory 
strain 
NDM-
1 
na R R S R S R R R 
DH10B Laborat
ory 
strain 
IMP-1 na R R S S S ++
+ 
+++ ++++ 
18-M3-Ec-
Col-R 
Human 
(stool; 
2015) 
– d ST1
41 
S S S S R + ++ R 
26-Ec-Col-
R 
Human 
(stool; 
2015) 
– ST6
9 
S S S S R R R R 
ATCC 
35218 
Laborat
ory 
strain 
– na S S S S S + + R 
ST, sequence type; CTX, cefotaxime; IPM, imipenem; CIP, ciprofloxacin; GEN, 
gentamicin; COL, colistin, R, resistant; I, intermediate; S, susceptible; na, not available. 
a Most STs were obtained with the Warwick scheme 
(http://enterobase.warwick.ac.uk/species/index/ecoli); those indicated in italic were 
obtained with the Pasteur scheme (http://bigsdb.web.pasteur.fr/). 
b European Committee on Antimicrobial Susceptibility Testing (EUCAST) v.6.0. 
c Strains were defined as susceptible to the bacteriophages when confluent lysis (i.e. 
complete clearing: ‘++++’), semiconfluent lysis (i.e. clearing throughout but with faintly 
32 
 
hazy background: ‘+++’), opaque lysis (i.e. turbidity throughout the cleared zone: ‘++’) or 
‘tâches vièrges’ (i.e. a few individual clear or opaque plaques: ‘+’) was recorded. Strains 
showing no activity (i.e. no clearing: ‘R’) were defined as resistant. 
d – Indicates no bla genes conferring resistance to extended-spectrum cephalosporins. 
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Table 2 
Characteristics of the 21 Proteus mirabilis and 10 Proteus vulgaris strains and their 
susceptibility to three commercial bacteriophage cocktails 
Strain ID Specie
s 
Origin 
(source; 
year of 
isolation
) 
Main 
bla 
gene
s 
Susceptibility 
according to 
EUCAST a 
Bacteriophage 
susceptibility b 
CT
X 
IP
M 
CI
P 
GE
N 
PY
O 
INTES
TI 
Septaph
age 
VB1248 P. 
mirabi
lis 
Human 
(blood; 
2009) 
VEB-
6 
R S R R + + +++ 
16B P. 
mirabi
lis 
Turkey 
meat 
(2012) 
VEB-
6 
R S R R ++ +++ ++++ 
17B P. 
mirabi
lis 
Turkey 
meat 
(2012) 
VEB-
6 
R S R R ++ ++ ++++ 
5705.10 P. 
mirabi
lis 
Human 
(urine; 
2015) 
VEB-
1-
like 
R S R I ++
+ 
+++ +++ 
1409101
274 
P. 
mirabi
lis 
Human 
(na; 
2014) 
CTX-
M-9-
like 
R S na na ++ ++ R 
5304.28 P. 
mirabi
lis 
Human 
(urine; 
2013) 
TEM-
3-
like 
R S R R R R R 
5809.58 P. 
mirabi
lis 
Human 
(absce
ss; 
2015) 
TEM-
3-
like 
R S R R R R R 
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Strain ID Specie
s 
Origin 
(source; 
year of 
isolation
) 
Main 
bla 
gene
s 
Susceptibility 
according to 
EUCAST a 
Bacteriophage 
susceptibility b 
CT
X 
IP
M 
CI
P 
GE
N 
PY
O 
INTES
TI 
Septaph
age 
4810.05 P. 
mirabi
lis 
Human 
(urine; 
2011) 
CMY-
2 
R S I S R R R 
4810.40 P. 
mirabi
lis 
Human 
(blood; 
2011) 
CMY-
2 
R S R S R R R 
4812.18 P. 
mirabi
lis 
Human 
(urine; 
2011) 
CMY-
2 
R S R S R R R 
5106.42 P. 
mirabi
lis 
Human 
(wound
; 2012) 
CMY-
2 
R S R S R R R 
804133-
Nr.6 
P. 
mirabi
lis 
Human 
(na; 
2014) 
CMY-
2-
like 
R S R R ++
+ 
+++ R 
15D P. 
mirabi
lis 
Chicken 
meat 
(2012) 
CMY-
2 
I S S S R R R 
5909.63 P. 
mirabi
lis 
Human 
(urine; 
2015) 
CTX-
M-9-
/CM
Y-2-
like 
R S I R R R R 
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Strain ID Specie
s 
Origin 
(source; 
year of 
isolation
) 
Main 
bla 
gene
s 
Susceptibility 
according to 
EUCAST a 
Bacteriophage 
susceptibility b 
CT
X 
IP
M 
CI
P 
GE
N 
PY
O 
INTES
TI 
Septaph
age 
6012.36 P. 
mirabi
lis 
Human 
(stool; 
2016) 
NDM-
1-
/CM
Y-2-
like 
R R R R R R R 
6012.61 P. 
mirabi
lis 
Human 
(blood; 
2016) 
– c S S S S R ++ + 
6012.72 P. 
mirabi
lis 
Human 
(blood; 
2016) 
– S S S S R R R 
6103.33 P. 
mirabi
lis 
Human 
(blood; 
2016) 
– S S S S R + R 
6107.51 P. 
mirabi
lis 
Human 
(blood; 
2016) 
– S S S S R R R 
6202.32 P. 
mirabi
lis 
Human 
(blood; 
2016) 
– S S S S ++
+ 
++++ +++ 
6204.01 P. 
mirabi
lis 
Human 
(blood; 
2016) 
– S S S S R + R 
5307.35 P. 
vulgar
is 
Human 
(blood; 
2013) 
– S S S S R R R 
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Strain ID Specie
s 
Origin 
(source; 
year of 
isolation
) 
Main 
bla 
gene
s 
Susceptibility 
according to 
EUCAST a 
Bacteriophage 
susceptibility b 
CT
X 
IP
M 
CI
P 
GE
N 
PY
O 
INTES
TI 
Septaph
age 
5307.79 P. 
vulgar
is 
Human 
(blood; 
2013) 
– S S S S R R R 
5408.26 P. 
vulgar
is 
Human 
(blood; 
2014) 
– S S S S R R R 
5410.37 P. 
vulgar
is 
Human 
(blood; 
2014) 
– S S S S R R R 
5502.26 P. 
vulgar
is 
Human 
(blood; 
2014) 
– S S S S R R R 
5507.56 P. 
vulgar
is 
Human 
(blood; 
2014) 
– S S S S R R R 
5801.02 P. 
vulgar
is 
Human 
(blood; 
2015) 
– S S S S R R R 
5906.65 P. 
vulgar
is 
Human 
(blood; 
2015) 
– S S S S R R R 
6202.78 P. 
vulgar
is 
Human 
(urine; 
2016) 
– S S S S ++ ++ R 
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Strain ID Specie
s 
Origin 
(source; 
year of 
isolation
) 
Main 
bla 
gene
s 
Susceptibility 
according to 
EUCAST a 
Bacteriophage 
susceptibility b 
CT
X 
IP
M 
CI
P 
GE
N 
PY
O 
INTES
TI 
Septaph
age 
6208.26 P. 
vulgar
is 
Human 
(blood; 
2016) 
– S S S S + + R 
CTX, cefotaxime; IPM, imipenem; CIP, ciprofloxacin; GEN, gentamicin; R, resistant; I, 
intermediate; S, susceptible; na, not available. 
Proteus spp. is naturally resistant to colistin. 
a European Committee on Antimicrobial Susceptibility Testing (EUCAST) v.6.0. 
b Strains were defined as susceptible to the bacteriophages when confluent lysis (i.e. 
complete clearing: ‘++++’), semiconfluent lysis (i.e. clearing throughout but with faintly 
hazy background: ‘+++’), opaque lysis (i.e. turbidity throughout the cleared zone: ‘++’) 
and ‘tâches vièrges” (i.e. a few individual clear or opaque plaques: ‘+’) was recorded. 
Strains showing no activity (i.e. no clearing: ‘R’) were defined as resistant. 
c – Indicates no bla genes conferring resistance to extended-spectrum cephalosporins. 
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Table 3 
Summary of the susceptibility of the Escherichia coli and Proteus spp. strains to three 
commercial bacteriophage cocktails  
Phage cocktail/strain group Results of the spot test (%) a 
R + ++ +++ ++++
PYO Bacteriophage (Eliava) 
Overall strains (n = 101) 48.5 25.7 9.9 9.9 5.9 
E. coli (n = 70) 38.6 34.3 8.6 10.0 8.6 
Only ESBLs (n = 37) 45.9 32.4 10.8 5.4 5.4 
Only pAmpCs (n = 21) 28.6 38.1 4.7 9.5 19.0 
Carbapenemases (n = 7) 28.6 14.3 14.3 42.8 0 
ST131 or ST648 (n = 7) 28.6 14.3 28.6 14.3 14.3 
Proteus spp. (overall, n = 31) 70.9 6.4 12.9 9.7 0 
Proteus mirabilis (n = 21) 66.7 4.7 14.3 14.3 0 
MDR (n = 15) b 60.0 6.7 20.0 13.3 0 
Proteus vulgaris (n = 10) 80.0 10.0 10.0 0 0 
INTESTI Bacteriophage (Eliava) 
Overall strains (n = 101) 41.6 30.7 9.9 11.8 5.9 
E. coli (n = 70) 32.8 38.6 8.6 12.8 7.1 
Only ESBLs (n = 37) 43.2 40.5 2.7 8.1 5.4 
Only pAmpCs (n = 21) 14.3 42.8 9.5 23.8 9.5 
Carbapenemases (n = 7) 28.6 14.3 28.6 14.3 14.3 
ST131 or ST648 (n = 7) 28.6 14.3 14.3 42.8 0 
Proteus spp. (overall, n = 31) 61.3 12.9 12.9 9.7 3.2 
P. mirabilis (n = 21) 52.4 14.3 14.3 14.3 4.7 
MDR (n = 15) b 60.0 6.7 13.3 20.0 0 
P. vulgaris (n = 10) 80.0 10.0 10.0 0 0 
Septaphage (Biochimpharm) 
Overall strains (n = 101) 88.1 2.9 0 2.9 5.9 
E. coli (n = 70) 91.4 2.8 0 0 5.7 
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Only ESBLs (n = 37) 97.3 0 0 0 2.7 
Only pAmpCs (n = 21) 85.7 9.5 0 0 4.7 
Carbapenemases (n = 7) 71.4 0 0 0 28.6 
ST131 or ST648 (n = 7) 100 0 0 0 0 
Proteus spp. (overall, n = 31) 80.6 3.2 0 9.7 6.4 
P. mirabilis (n = 21) 71.4 4.7 0 14.3 9.5 
MDR (n = 15) b 73.3 0 0 13.3 13.3 
P. vulgaris (n = 10) 100 0 0 0 0 
ESBL, extended-spectrum -lactamase; pAmpC, plasmid-mediated AmpC -lactamase; 
MDR, multidrug-resistant. 
a Strains were defined as susceptible to the bacteriophages when confluent lysis (i.e. 
complete clearing: ‘++++’), semiconfluent lysis (i.e. clearing throughout but with faintly 
hazy background: ‘+++’), opaque lysis (i.e. turbidity throughout the cleared zone: ‘++’) or 
‘tâches vièrges’ (i.e. a few individual clear or opaque plaques: ‘+’) was recorded. Strains 
showing no activity (i.e. no clearing: ‘R’) were defined as resistant. 
b Including 7 ESBL-producers, 6 pAmpC-producers, 1 with CTX-M-9-/CMY-2-like and 1 
carbapenemase (NDM)-producer. 
 
